The FDA has approved Allergan's once-daily prescription eyedrops Lumigan as a first-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension. The first-line indication is in addition to Lumigan's established use as a second-line treatment, approved by the FDA in 2001.

Elevated IOP is a major risk factor for vision loss associated with open-angle glaucoma. The higher the IOP, the greater the likelihood of optic nerve damage, which can lead to vision loss and potential blindness. Lumigan (bimatoprost ophthalmic solution) monotherapy has been shown to effectively lower IOP.